Biohaven (BHVN) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Maze Therapeutics (MAZE) has outperformed Biohaven (BHVN) over the past year, losing 5.7% versus a loss of 29.9%. Biohaven is the larger company by market cap ($1.82 billion vs $1.51 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | MAZE |
|---|---|---|
| Share price | $12.08 | $27.11 |
| Market cap | $1.82B | $1.51B |
| 1-day change | +1.26% | +4.75% |
| YTD return | +7.00% | -34.56% |
| 1-year return | -29.89% | -5.74% |
| EPS (TTM) | $-4.62 | $-2.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-131.12M |
| 52-week high | $18.57 | $53.65 |
| 52-week low | $7.48 | $21.95 |
| Distance from 52-week high | -34.93% | -49.47% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +126.85% |
| Average volume | 2.61M | 563.38K |
| Shares outstanding | 151.04M | 55.55M |
| Employees | 274 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAZE has outperformed BHVN by 24.2 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
BHVN vs MAZE FAQ
Which is bigger, Biohaven or Maze Therapeutics?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.51B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, BHVN or MAZE?
MAZE returned -5.74% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Maze Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Biohaven and Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics.